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ABSTRACT  
       Objectives  
There is currently conflicting level 1 evidence in the use of long-term antibiotics for 
chronic rhinosinusitis without nasal polyps. The primary aim of this feasibility study was 
to optimise future randomised trial design by assessing recruitment and retention of 
patients alongside providing preliminary data on symptomatic control. 
 
Design  
Prospective, multi-centre feasibility (cohort) study with all patients receiving macrolide 
therapy for 12-weeks and a further subsequent 12-week follow-up. Participants received a 
12-week course of Clarithromycin 250mg alongside twice daily topical Mometasone and 
nasal douching. Primary outcomes focused on recruitment, retention and compliance. 
Clinical and quality-of-life outcomes measures were also recorded.   
 
Setting 
Patients were prospectively recruited from 6 UK outpatient clinics.  
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Participants 
Adult patients with chronic rhinosinusitis without nasal polyps and no prior endoscopic 
sinus surgery underwent baseline assessment and then follow-up at 3 and 6 months. 
Main outcome measures 
Six-month recruitment and retention data. 
 
Results 
Over 13 months, 55 adults were recruited from 5 centres. Four patients declined 
participation. 75% of patients were retained within the study. Dropouts included 1 
medication contraindication, 3 unable to tolerate medication, 10 not attending full follow-
up. Sino Nasal Outcome Test-22 and endoscopic scores showed statistically significant 
improvement. No other clinical or quality-of -life assessment improvements were seen. 
 
Conclusion 
Retention and recruitment to a trial using long-term Clarithromycin to treat chronic 
rhinosinusitis without nasal polyps is achievable and this data will support a future 
Randomised Controlled Trial. The study provides vital insight into trial design thus 
informing UK research networks and rhinology researchers internationally.  
 
Key Words: Macrolides, Sinusitis, Clarithromycin, Feasibility 
 
INTRODUCTION 
Long-term macrolide therapy is recommended in the treatment of Chronic Rhinosinusitis 
(CRS)1. Its potential benefits were extrapolated from findings in the respiratory 
community where marked improvement in both chest and nasal symptoms were seen in 
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panbronchioliitis patients alongside prolonged survival rates2.  The anti-inflammatory 
effects of reducing cytokine activity and in turn reducing airway inflammation and mucus 
production are well documented3. In CRS there have only been two Randomised Control 
Trials (RCT) performed to date which show conflicting evidence; the efficacy of 
macrolides in treating the condition has been called into question due to this conflicting 
level 1 evidence4,5.  
 
The first double-blind RCT published showed a significant improvement in clinical scores 
(alongside other outcomes) with Roxithromycin in CRS without nasal polyps (CRSsNPs), 
particularly in the normal IgE subgroup4. A second RCT with a similar number of patients, 
using Azithromycin did not show a significant improvement between the macrolide and 
placebo group5. The Cochrane review into antibiotics for CRS concluded that Wallwork et 
al’s study supported the therapy but further large sample studies were required6. This was 
echoed in a recent meta-analysis which found limited data to support macrolide therapy in 
CRS7, stating further research is required. In addition it is recognised that the data from 
the most recent RCT5 may skew outcomes as the study recruited predominantly patients 
who had failed previous sinus surgery, and included mixed phenotypes, with both 
CRSwNP and CRSsNP. Potentially more patients with elevated IgE levels who may not 
respond to macrolide therapy were recruited, although subgroup analysis was not 
performed1. With the increasing emergence of antibiotic resistance it is important that 
clinicians use such medications responsibly8. In addition clarithromycin use is associated 
with an increased risk of cardiac death particularly in women9, hence evaluation of its use, 
especially in long-term therapy is essential. 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
A future RCT to clarify the use of macrolides in CRS must be sufficiently powered, use 
appropriate clinical assessment methods and ensure retention of patients leads to 
meaningful data collection. To inform this process we conducted a UK-based, multicenter 
feasibility study. The primary outcome measures were patient recruitment and retention to 
the study with secondary outcomes including assessment of medication tolerance and 
compliance to the study protocol. In addition feedback and clinical outcomes of the study 
are reported.  
 
MATERIALS AND METHODS  
Ethical Considerations 
Ethical approval was given to the study from the West Midlands Research Ethics 
Committee (reference: 12/WM/0359) and the study was included on the UK CRN 
portfolio (ref: 13417).  
 
Funding 
Funding for the study was partly provided by the Royal College of Surgeons of England 
(Pump Priming Grant) with support from the Anthony Long and Bernice Bibby Trusts.  
 
Methods 
The study was conducted as a multi-centre collaboration between 6 sites. Study centres 
included James Paget University Hospital (Great Yarmouth), Guys & St Thomas Hospital 
(London), Royal Surrey County Hospital (Guildford), Queens Medical Centre 
(Nottingham), Freeman Hospital (Newcastle) and Queen Elizabeth Hospital 
(Birmingham). As this was a feasibility study, no sample size was needed but a target 
recruitment of 50 patients over a 12-month period was established at the beginning. At the 
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beginning of the study, the Chief Investigator hosted a teleconference with Principal 
Investigators and Research Nurses at all sites included. 
Inclusion criteria 
Inclusion criteria comprised of adult patients between 18 and 70 years, with a diagnosis of 
CRSsNPs as per the EPOS guidelines (Fokkens, 2012) who had not received maximal 
medical treatment previously. Previous surgery was not a reason for exclusion although no 
patients had undergone previous endoscopic sinus surgery, one patient had undergone 
previous maxillary balloon sinuplasty.  
Exclusion criteria 
CRSwNP and secondary CRS (eg Wegner’s, immunodeficiency). 
 
Treatment Regime 
At all sites, patients received a 12-week course of Clarithromycin 250mg b.d. alongside 
b.d. nasal douching and intranasal mometasone, (2 squirts, each nostril b.d.), the latter two 
being continued for a further 12 weeks. Regarding the choice of macrolide used, 
Clarithromycin is a common macrolide used in the UK with broader microbial coverage 
than Erythromycin10.  
 
Participant Flow 
Patients diagnosed with CRSsNPs were recruited from the outpatient clinics at 
participating sites and subsequently underwent 2 face-to-face study visits and a third 
interaction via postal correspondence (questionnaires and feedback only). Patients who 
completed the study were asked to comment on their participation in the trial (see 
appendix 1). Baseline clinical assessment included endoscopy (scored using the Lund-
Kennedy endoscopic score11, mucocilliary clearance testing (saccharin test), smell testing 
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(Sniffin’ sticks), serum IgE levels, skin prick allergy testing and sinus CT with Lund-
Mackay scoring 12. All but the last 3 tests were repeated at visit 2 following the 12-week 
course of clarithromycin. The Sinonasal outcome test (SNOT-22 – a disease specific 
measure of HRQOL), SF-12 and EQ-5D questionnaires (both global measures of 
HRQOL13, 14, 15.) were completed at all 3 encounters.  
Statistical analysis  
Statistical analysis of continuous variables was performed using paired t-tests and non-
parametric tests used for non continuous data. In regards to SNOT22 scores, patients with 
a minimum clinical difference of 9 points on the SNOT-22 were considered to have had a 
clinical improvement in symptoms16.  
 
RESULTS 
Primary outcome measures 
Recruitment of patients 
Over a 13 month period (January 2013-January 2014) 55 patients were recruited from 5 
units, 51% were male and the mean age was 55 years (range from 21-81). Sixty-three 
patients were eligible but 8 declined. Despite ethical approval being confirmed in 
November 2012, it took until the following December for all 6 sites to finally complete 
research governance. At three sites, Research & Development offices chose to interpret 
the research protocol differently from the ethics committee resulting in a temporary 
suspension of the study for 2 weeks whilst the Medicines and Health Regulation Authority 
(MHRA) confirmed the study was not a Clinical Trial of an Investigational Medicinal 
Product (CTIMP). During the first 9 months of the study, only the lead site was open to 
recruitment leading to considerably different numbers of patient participating in each site 
(see table 1). 
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Retention of patients 
At the recruitment stage, one patient was excluded during preliminary work-up as 
clarithromycin was found to be contraindicated although underwent all of visit 1 before 
this was identified. Three further patients were unable to take the full course of 
clarithromycin due to side effects and 10 patients dropped out (see table 1). Compliance 
with the study protocol fell towards the end of the study with 55 patients attending visit 1, 
45 attending visit 2 and 41 completing visit 3.  Recruitment and retention rates varied 
considerably between hospitals, seen in table 1.  
 
Compliance with assessment and treatment 
Adherence to the study protocol varied between sites with poor compliance of the research 
staff in performing some clinical tests (see table 2). The use of the Sniffin’ Sticks was 
temporarily halted during the study due to confusion about their use (by the sponsor 
representative) and subsequently their status at MHRA, but this was later overturned and 
their use reinstated. The reasons for poor compliance to the protocol is varied, feedback 
from research nurses taking part can be seen in appendix 2. Logistical issues affected 
some sites e.g. difficulty getting hold of equipment (in particular Sniffin’ sticks kit). In 
addition poor conduct of the compulsory elements of the protocol in 1 centre were noted.  
 
Medication tolerance and compliance 
Three patients suffered adverse effects during taking the medication (acid reflux, skin 
reaction, gastrointestinal symptoms) and a fourth had headaches for the first 2 weeks 
which resolved enabling full completion of the 12 week course.  
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Secondary Outcomes 
Patient feedback 
Twenty-six patients responded to the postal questionnaire: 18 patient patients reported no 
negative aspects, the same number of patients would be happy to take part in a placebo 
study. Three patients reported issues with the clinical testing (discomfort during 
mucocillary clearance and sniffin’ stick testing). Constructive criticism regarding 
communication between the study centre and patients/GP, was also made. Patients also 
raised the question about the possibility of breaking the blinding process if there was no 
symptomatic improvement in a placebo-controlled trial.  
 
Staff feedback  
It came apparent during running the trial that experience of the research nurses (RN) 
involved in the trial was of differing levels from an experienced ENT trained RN (site 1), 
to experienced (but not ENT trained) RN (site 3), to inexperienced RN (site 6).. There 
were issues with implementation of the protocol, specifically using up-to date 
questionnaires and performing the compulsory tests. Unofficial feedback from clinicians 
also highlighted the fact that some RNs were unfamiliar with certain clinical tests (Sniffin’ 
sticks) and the length of time this took to perform such aspects reflected negatively on 
patient recruitment (seen at site 6 where the RN actively discouraged patients from taking 
part due to the perceived time to perform the test).  
 
Clinical Outcomes 
Table 3 shows the clinical results from this feasibility study. Excluding the 4 patients 
unable to take their medication due contraindications/side effects, 45 and 41 patients 
completed all surveys at visits 2 and 3 respectively. Statistically significant reduction in 
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SNOT-22 scores were found at both 3 and 6 months. This was clinically significant (score 
reduction of 9 points or greater16) in 22/45 and 20/40 patients at 3 and 6 months 
respectively. Endoscopic scores also showed a statistically significant improvement. 
Positive mucopus culture were seen in 12 patients as baseline assessment.  
 
No other statistically significant result was seen in other clinical outcomes of mucocillary 
clearance and smell testing. Serum IgE levels were recorded in 50 patients at visit 1, 43 
patients had both IgE levels and 12-week SNOT-22 data (see table 4). A greater 
proportion of responders to therapy were seen in the patients with elevated IgE levels 
although this was not significant (69% vs 47%; p = 0.212) in contrast to the previous 
RCT5.  
Low levels of inhalant screen positivity were seen in allergy testing (performed in 51 
patients overall, 50 of whom has RAST and 1 skin prick testing), 9 patients demonstrated 
inhalant screen positivity, 5 of such patients had elevated IgE also.  
  
Lund-Mackay (LM) scoring of CT-paranasal sinuses was performed in 54 patients. There 
was no significant correlation between LM score and symptomatic improvement following 
treatment using the clinically significant SNOT-22 score (p = 0.636). At site 1 the number 
of patients progressing to surgery was 12 of the 35 patients (34%) completing the study 
(11 undergoing sinus surgery, 1 undergoing septoplasty).   
 
Patient reported outcomes 
EQ-5D analysis showed no statistical difference in either mean VAS score or any of the 5 
health dimensions (seen in Figure 1a-1e) although patients reported higher rates of 
pain/discomfort and anxiety/depression. 
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SF-12 scores (both Mental and Physical Component) increased at both visits 2 and 3 from 
baseline. The improvements were modest and did not improve to that above the score 
expected for a ‘typical adult’.  
 
DISCUSSION  
Synopsis of key findings 
We aimed to investigate the feasibility of a 6-month trial where clarithromycin was given 
for 12-weeks showed a recruitment rate of 83% and a retention rate of 76%. There was an 
average recruitment rate of 4.23 per month across all sites in the latter part of the study. 
Compliance to the study protocol varied from site to site, specific issues regarding this are 
discussed below. The lead site recruited significantly more patients (recruitment rate of 
3.17/month) with good retention rates of 92%, the results are somewhat skewed by the 
poor retention rates in some other centres.  This initiates a discussion about factors that 
contributed to the variation seen and how these could be managed to improve overall 
study retention and data collection. Recognising these issues is vital in planning a future 
RCT. 
 
Comment on recruitment, retention and study protocol 
The results show a failure of comprehensive data collection at all sites. An incorrect 
version of one study questionnaire was uploaded onto the central study site at the start of 
recruitment which caused some understandable confusion. At one centre, the RN 
misinterpreted the requirement to perform other outcome measures from the protocol 
hence reducing clinical and questionnaire outcomes further. At another site, 8 patients 
identified by initial screening failed to consent after assessment with an inexperienced 
generic research nurse, and no patients at this site ever joined the study. Time to perform 
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outcome tests was cited as the greatest barrier to participation. It is notable that the RN at 
this site took over 45 minutes to perform olfactory testing, compared to 20 min by an 
experienced research nurse. Lastly the reduced number at some sites were in part due to 
significant delays in research governance approval meaning some centres were unable to 
recruit until the last 4 months. These difficulties were in stark contrast to the lead site 
which had an experienced research nurse with an ENT background who successfully 
recruited patients to the study throughout the 13 month duration with the loss of only 3 
patients (2 due to drug side effects and 1 drop-out). 
 
The experience of the research nurses at the individual sites had a big impact on their 
ability to both recruit patients and perform the relevant investigations, despite a 
teleconference at the beginning of the study to talk through the flowchart. This has 
demonstrated a clear need for a specific training day for all research nurses involved in 
any future trial. Research nurse support provided by UK local clinical research networks 
(LCRNs) is often generic in nature but will vary from site to site. Any future RCT would 
include a study training day to ensure all staff undergo standardised training and has also 
inspired a national ENT study day for all generic research nurses. Due to the limited 
funding for this study, a centralised database was not available, but this would be 
mandatory if a formal RCT is funded in due course, to allow for ease of secure data entry 
at site visits. This feasibility study has identified significant issues for reflection if a full 
scale RCT is to be conducted effectively. In addition 93% patients were able to take the 
full course of therapy without significant side effects with only 3 subjects unable to 
tolerate clarithromycin and with appropriate screening, no serious adverse events, despite 
concerns from recent publications9.  There is a growing body of evidence (published after 
study design) that macrolide therapy in those with previous ischaemic heart disease or 
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prolonged QT-interval on ECG is associated with cardiac toxicity. While no patients in 
this feasibility study suffered such side effects, the cohort was small and hence any future 
RCT should exclude patients with such risk factors and include an ECG in pre-treatment 
investigations 17, 18.  
 
Clinical results and comparison to other studies 
It must be emphasized that this is not a placebo-controlled trial and that without a control 
arm the effect of intranasal corticosteroids and douching cannot be assessed. While the 
clinical results from this case cohort study suggests that a longer-term course of macrolide 
therapy may be therapeutically advantageous in up to 50% of patients with CRSsNPs, no 
firm conclusions regarding clinical effectiveness can be made without a control arm. 
However, the response rate seen in this feasibility study provides valuable information for 
trialists considering a formal RCT, as it can inform power calculations. In addition it is 
notable that no other clinical indicators (e.g. mucocillary clearance, smell testing) nor 
generic quality of life assessment showed any statistically significant improvement. The 
results support the need for a further RCT as suggested by a recent meta-analysis7 which 
found limited data to support such therapy. In addition, within the wider medical 
community it is vital to ensure long-term macrolides are used responsibly in the face of 
increasing antimicrobial resistance.  
 
This study was designed to capture potential issues prior to recruiting to a full RCT. 
Limitations in study design can be acted upon at this early stage, such as the limited data 
collected to assess patient compliance with medication. The study relied purely on patient 
self-reporting and in the future questionnaires/diaries could be used to clarify this further. 
As patients also raised concerns regarding the time taken to complete outcome 
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assessments, the number of outcome measures should be re-evaluated prior to a formal 
RCT to minimise participant burden and maximize recruitment. Encouragingly many 
patients reported positive experiences regarding study involvement and were happy to take 
part in a placebo-controlled trial.  
 
CONCLUSION  
This paper presents an honest account of the issues encountered when conducting a multi-
centre clinical trial. The issues identified have been integral in informing study design for 
a future RCT into macrolide therapy. In addition, we are keen to share our experiences 
with other researchers in order to reduce research waste through poor recruitment and 
retention which can lead to both under-powered and/or unfinished trials. This is in keeping 
with advice in avoiding research waste as identified by Chalmers and Glasziou19. Clinical 
trials require extensive time and financial commitment. It is the responsibility of 
researchers to ensure patients who relinquish their time to participate in trials are recruited 
to well-designed, well-conducted studies; a feasibility study is an essential part of this 
process.  
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Figure Legend 
Figure 1a-e: The EQ-5D data is presented as percentage of patients reporting each level in 
each of the 5 dimensions at the 3 separate visits. Patients were self-caring, with good 
mobility (level 1) but had higher rates of problems with anxiety/depression and 
pain/discomfort. The 2 latter dimensions worsened in some patients at 6-month.  
LEGEND: baseline – black; 3-months – dark grey; 6-months light grey. 
 
Table 1 
Centre No. 
Visit 1 
completion 
Visit 2 
completion 
Visit 3 
completion 
Reason for dropout 
1 38 36 35 2 – clarithromycin side 
effects; 1 DNA 
2 7 1 1 6 DNA 
3 6 4  3 1 – clarithromycin 
contraindicated; 2 DNA)
4 1 1 1 - 
5 3 2 1 1 – clarithromycin side 
effects; 1 DNA 
6 0 - - Patients deterred by RN 
 
Table 1 shows the recruitment and retention rates at each of the 6 centres and summarises 
the reason for dropout, (DNA = did not attend).  
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Table 2 Visit 1 completion Visit 2 completion Visit 3 completion 
SNOT-22 Q 54/55 45/51 41/51 
SF-12 Q 53/55 44/51 41/51 
EQ-5D Q 53/55 44/51 41/51 
Endoscopic score 38/55 29/51 N/A 
Saccharin Test 54/55 42/51 N/A 
Smell Testing 49/55 36/51 N/A 
IgE levels 50/55 N/A N/A 
Allergy testing 51/55 N/A N/A 
LM score 54/55 N/A N/A 
 
Table 2 shows the completion rates of each study component at the 3 study visits with 
total completion numbers shown before elimination for dropouts/intolerance etc taken into 
account. Only the first 3 components were required at visit 3. (Q = questionnaire). Allergy 
testing was either with skin prick tests or RAST.  
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Table 3. 
 
Test Result (standard deviation) 
Clinical test (number of 
patients at Baseline/3 
months/12months 
Baseline 3 months p-value 6 months p-value 
SNOT22 total score 
(54/45/41) 
41.09 
(21.765) 
33.29 
(23.96) 
0.01 31.48 
(24.36) 
0.03 
SNOT22 clinically 
significant* 
 22/45 
patients 
(48.9%) 
- 20/40 
patients 
(50%) 
- 
Endoscopic score 
(38/29) 
3.31 
(1.26) 
1.4 
(1.56) 
0.000   
Smell Testing 
(49/36) 
24.05 
(9.45) 
23.69 
(9.99) 
0.983   
Saccharin Test  
(seconds) (54/42) 
800.44 
(376.72) 
818.97 
(531.25) 
0.274   
IgE levels (ku/l)  
(50) 
100.7 
(114.48) 
 -   
Allergy testing 
Positive result 
9/50 
patients 
 -   
LM score 
(54) 
8.65 (4.72)     
SF-12      Mental 46.82 
(11.96) 
47.05 
(47.05) 
0.705 49.33 
(11.13) 
0.617 
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        Physical 
47.7 
(10.64) 
48.91 
(11.04) 
0.279 47.63 
(10.04) 
0.515 
EQ-5D    VAS 75.59 
(20.95) 
76.64 
(21.65) 
0.967 75.7 (19.40) 0.648 
 
Table 3 shows the raw data for each of the clinical components of the study. *Clinically 
significant improvement in SNOT22 score (>9 points)16. NS = not significant 
 
 
 
Table 4 SNOT22 clinical 
improvement (≥9 points) 
SNOT22 no clinical 
improvement 
IgE elevated 9 4
IgE normal 14 16
 
Table 4 shows the proportions of IgE positive and negative patients with significant 
clinical improvement in SNOT22 scores.  
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